Liverpool Uni Secures Funds to Boost Long-Acting Therapies miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
As a major trade exhibition for the laboratory industry, this year’s Lab Innovations will draw together leading professionals, scientists and research communities, with a focus on driving innovation and sustainability. Click to read more.
AZoRobotics speaks to Prof Matt Reed, Strategy Director for the Materials Innovation Factory at the University of Liverpool, about how the application of industry 4.0 technologies such as robotics and automation can unlock chemistry and advanced materials research and innovation.
Repurposing an existing, cheap drug into long-acting injectable therapy to treat Covid-19
Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.
In a paper published in the journal
Nanoscale, researchers from the University s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate the nanoparticle formulation of niclosamide, a highly insoluble drug compound, as a scalable long-acting injectable antiviral candidate.
The team started repurposing and reformulating identified drug compounds with the potential for COVID-19 therapy candidates within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified and has been shown to be highly effective against SARS-CoV-2 in a number of laboratory studies.
Researchers find potential route to COVID-19 therapy
ANI
06 May 2021, 03:27 GMT+10
Liverpool [UK], May 5 (ANI): Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.
In a paper published in the journal Nanoscale, researchers from the University s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate the nanoparticle formulation of niclosamide, a highly insoluble drug compound, as a scalable long-acting injectable antiviral candidate.
The team started repurposing and reformulating identified drug compounds with the potential for COVID-19 therapy candidates within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified and has been shown to be highly effective against SARS-CoV-2 in a number of laboratory studies.